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Brain metastasis (BM) is a deadly complication that occurs in 
an estimated 10% to 20% of all cancer patients, most frequently 
originating from lung cancer, breast cancer, and cutaneous mela-
noma.1 Often, it can be the initial presenting manifestation in 
patients with otherwise previously undiagnosed advanced stage 
cancer. Due to the dismal prognosis of this clinical complication, 
efficient and effective diagnosis and treatment are crucial.
Valuable information used to guide therapeutic approaches 
can be derived from the status of the systemic disease, patient’s 
performance status, number, size and location of BM, and 
direct BM profiling, which can provide actionable alterations 
and aid in both diagnosis and prognosis of the disease. 
Exemplifying the importance of profiling of BM specimens, a 
recent study found that 53% of BMs have clinically informa-
tive molecular alterations not detected in the matched primary 
tumor.2 Furthermore, in some cases, the accurate diagnosis of 
BM may be challenging for pathologists and clinicians, espe-
cially when the availability of BM surgical specimens is limited 
and/or when a BM is poorly differentiated. These challenges 
highlight the need to profile BM tissue directly to properly 
determine an accurate therapeutic approach.
In recent years, innovative studies have demonstrated the 
ability of DNA methylation profiling to aid in the diagnosis of 
cancers from unknown primary sites,3 primary central nervous 
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system (CNS) tumors,4–6 and other primary neoplasms.7–9 
Given the potential clinical utility of DNA methylation profil-
ing and leveraging on the findings of our seminal studies,10–12 
we recently aimed to complement these disease-specific epige-
netic classifiers by first generating unique DNA methylation 
signatures of the most frequent types of metastatic brain tumors, 
followed by developing an efficient system to aid in the diagno-
sis of challenging cases by using a relatively small portion of 
BM tissue.13 With this goal in mind, we focused on identifying 
informative combinations of genomic regions whose DNA 
methylation level could predict the type of brain tumor, the tis-
sue of origin, and therapeutically relevant subtypes of metastatic 
brain tumors.13 To generate high-quality genome-wide DNA 
methylomes that could be easily compared with data from other 
studies, we analyzed genomic DNA derived from micro-dis-
sected formalin-fixed paraffin-embedded (FFPE) BM speci-
mens with the Infinium HumanMethylation 450K (HM450K) 
microarray.14 In our study, we included specimens from lung 
cancer brain metastases (LCBMs), breast cancer brain metasta-
ses (BCBMs), and melanoma brain metastases (MBMs), the 
three most frequent types of BM. In addition, we included BM 
specimens from patients with uncertain or incomplete histopa-
thology diagnosis. We further integrated publicly available 
large-scale data from a variety of brain and extracranial primary 
tumors and employed machine learning algorithms to build 
robust BM classifiers.
2 Epigenetics Insights 
Our study resulted in a three-step brain metastasis DNA 
methylation (BrainMETH) classification system capable of 
distinguishing (1) BM from primary brain tumors 
(BrainMETH classifier A), (2) the tissue of origin of the 
BM specimen (BrainMETH classifier B), and (3) the thera-
peutically relevant subtype of BM specimens in breast cancer 
patients (i.e. hormone receptor–positive/HER2-negative, 
HER2-positive and triple-negative breast cancer, BrainMETH 
classifier C; Figure 1).13 These classifiers demonstrated an 
excellent ability to determine the origin and therapeutic sub-
type of metastatic brain tissues, even for cases with unknown or 
uncertain initial diagnosis, missing information, and patients 
with synchronous or asynchronous brain lesions. To further the 
translation of these findings into clinical practice, we selected 
the most informative genomic regions and designed specific 
targeted DNA methylation assays using quantitative methyla-
tion-specific polymerase chain reaction (qMSP). This cost-
effective approach showed excellent efficiency in accurately 
diagnosing both primary and metastatic brain tumors of vari-
ous origins.
To ensure the reproducibility of these findings and increase 
the utility of the data generated from this study, we deposited 
the raw methylation data to the National Center for 
Biotechnology Information (NCBI)’s Gene Expression 
Omnibus (GEO) repository (GSE108576 and GSE44661) 
and provided all the relevant clinical information for patients 
included in the study as part of a separate article.14 This 
resource supports interoperability and wider use by the biosci-
ence community by providing a manually curated data set in 
the Investigation-Study-Assay (ISA) framework that includes 
the clinical-demographic information for all the patients linked 
to the respective raw DNA methylation data (.idat) files. In 
addition to the standardization for downstream data analysis 
provided by the ISA framework, we believe that this resource 
will not only allow for the replication of each step of our study 
but will also facilitate the translation of these data into addi-
tional practical histomolecular applications.14
Additional expansion of the BrainMETH classifier would 
involve the evaluation of BM from less frequent origins, such 
as renal or colorectal carcinoma that were not covered in our 
studies. As recently demonstrated for glioblastoma, a potential 
limitation of these analyses is the presence of intra-tumor 
DNA methylation heterogeneity.15 Perhaps this, as well as 
other disease-specific features, should be considered in future 
work to improve and expand the applicability of DNA methyl-
ation–based diagnostic signatures for clinical use.
The acquisition of samples for accurate diagnosis can be 
challenging in some patients with brain neoplasms due to sev-
eral factors, such as anatomical location or extensive metastatic 
disease (making patients poor candidates for neurosurgery). 
Establishing a minimally invasive approach to identify thera-
peutic targets, diagnose, classify, and potentially follow-up 
BM lesions will significantly impact the management of 
patients with brain neoplasms. Recent next-generation 
sequencing-based approaches have shown that BM can be 
profiled using cell-free DNA (cfDNA) extracted from cere-
brospinal fluid (CSF) without the need for surgical interven-
tion.16,17 We speculate that the adaptation of the BrainMETH 
classifier and CNS tumor DNA methylation classifiers to 
cfDNA derived from pre-surgical CSF specimens may sig-
nificantly impact patient management, leading to a reduction 
of invasiveness, especially for those patients with uncertain 
diagnosis and inoperable brain tumors.
Given the impactful clinical applications of DNA methyla-
tion analysis, we believe that the clinical and epigenetic data 
generated in our study can be easily adapted to expand the 
applications of the BrainMETH classifier and to identify new 
epigenetic signatures involved in the BM etiology. Specifically, 
the adaptation and validation of these epigenetic classifiers to 
streamlined polymerase chain reaction (PCR)-based assays 
Figure 1. Application of the BrainMETH classifiers for the stratification of multiple brain tumors: (A) Distances between primary brain tumors 
(glioblastoma; purple branches; n = 60) and brain metastases (BMs; red branches; n = 94) using the DNA methylation levels of genomic regions included in 
the BrainMETH classifier A. (B) Distances between metastatic brain tumors from patients with primary lung cancer (LCBM; blue branches; n = 22), breast 
cancer (BCBM; pink branches; n = 28), and melanoma (MBM; brown branches; n = 44) using the DNA methylation levels of genomic regions included in the 
BrainMETH classifier B. (C) Distances between brain metastases from different breast cancer therapeutic subtypes including hormone receptor 
(HR)-positive/HER2-negative BCBMs (green branches; n = 13), HER2-positive BCBMs (blue branches, n = 13), and HR-/HER2- (a.k.a. triple-negative 
breast cancer) BCBM (red branches; n = 5) using the DNA methylation levels of genomic regions included in the BrainMETH classifier C. The phenetic 
trees were generated using the Pearson’s Correlation as a distance metric, with average linkage as clustering approach in the FigTree, version 1.4.3, tool 
with radial tree layout.
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may allow a wide range of laboratories to assay patient-derived 
tumors in a cost-effective manner.
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